Derek J Hausenloy

List of Publications by Year
in descending order

333 papers	32,843 citations	4658 85 h-index	4548 171 g-index
356 all docs	356 docs citations	356 times ranked	24289 citing authors

#	Article	IF	Citations
1	Myocardial Reperfusion Injury. New England Journal of Medicine, 2007, 357, 1121-1135.	27.0	3,156
2	Myocardial ischemia-reperfusion injury: a neglected therapeutic target. Journal of Clinical Investigation, 2013, 123, 92-100.	8.2	1,687
3	New directions for protecting the heart against ischaemiaâ€“reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovascular Research, 2004, 61, 448-460.	3.8	873
4	Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury. Circulation, 2010, 121, 2012-2022.	1.6	845
5	Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. New England Journal of Medicine, 2015, 373, 1408-1417.	27.0	603
6	Postconditioning: A Form of â€œModified Reperfusionâ€•Protects the Myocardium by Activating the Phosphatidylinositol 3-Kinase-Akt Pathway. Circulation Research, 2004, 95, 230-232.	4.5	602
7	Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet, The, 2007, 370, 575-579.	13.7	598
8	Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. , 2018, 186, 73-87.		533
9	Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning. Pharmacological Reviews, 2014, 66, 1142-1174.	16.0	521
10	Evaluation of Techniques for the Quantification of Myocardial Scar of Differing Etiology Using Cardiac Magnetic Resonance. JACC: Cardiovascular Imaging, 2011, 4, 150-156.	5.3	514
11	Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovascular Research, 2002, 55, 534-543.	3.8	487
12	Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury. Journal of the American College of Cardiology, 2019, 73, 89-99.	2.8	484
13	Postconditioning and protection from reperfusion injury: where do we stand? * Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2010, 87, 406-423.	3.8	447
14	Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovascular Research, 2008, 79, 377-386.	3.8	440
15	Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Failure Reviews, 2007, 12, 217-234.	3.9	436
16	Survival kinases in ischemic preconditioning and postconditioning. Cardiovascular Research, 2006, 70, 240-253.	3.8	425
17	Ischaemic conditioning and reperfusion injury. Nature Reviews Cardiology, 2016, 13, 193-209.	13.7	419
18	Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H971-H976.	3.2	416

#	Article	IF	Citations
19	The Reperfusion Injury Salvage Kinase Pathway: A Common Target for Both Ischemic Preconditioning and Postconditioning. Trends in Cardiovascular Medicine, 2005, 15, 69-75.	4.9	395
20	Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemiaâ€“reperfusion injury. Cardiovascular Research, 2003, 60, 617-625.	3.8	350
21	Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. New England Journal of Medicine, 2019, 380, 2418-2428.	27.0	326
22	Transient Mitochondrial Permeability Transition Pore Opening Mediates Preconditioning-Induced Protection. Circulation, 2004, 109, 1714-1717.	1.6	319
23	Myocardial reperfusion injury: looking beyond primary PCI. European Heart Journal, 2013, 34, 1714-1722.	2.2	318
24	Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Research in Cardiology, 2018, 113, 39.	5.9	311
25	The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology, 2003, 35, 339-341.	1.9	301
26	Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 19-34.	3.8	284
27	Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 564-585.	3.8	278
28	Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart, 2012, 98, 1436-1441.	2.9	276
29	The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. Journal of Molecular and Cellular Cardiology, 2015, 78, 23-34.	1.9	263
30	Ischaemic conditioning and targeting reperfusion injury: a 30Âyear voyage of discovery. Basic Research in Cardiology, 2016, 111, 70.	5.9	257
31	Mitochondrial morphology and cardiovascular disease. Cardiovascular Research, 2010, 88, 16-29.	3.8	254
32	Preconditioning and postconditioning: Underlying mechanisms and clinical application. Atherosclerosis, 2009, 204, 334-341.	0.8	253
33	Preconditioning and postconditioning: United at reperfusion. , 2007, 116, 173-191.		246
34	T1 Mapping for Myocardial Extracellular Volume Measurement by CMR. JACC: Cardiovascular Imaging, 2013, 6, 955-962.	5.3	245
35	Cardiac MRI Endpoints in MyocardialÂInfarction Experimental andÂClinicalÂTrials. Journal of the American College of Cardiology, 2019, 74, 238-256.	2.8	235
36	Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Cardiovascular Research, 2007, 75, 530-535.	3.8	232

#	Article	IF	Citations
37	The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Research in Cardiology, 2009, 104, 189-202.	5.9	230
38	Preconditioning the Diabetic Heart: The Importance of Akt Phosphorylation. Diabetes, 2005, 54, 2360-2364.	0.6	228
39	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet, The, 2019, 394, 1415-1424.	13.7	223
40	Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. European Heart Journal, 2017, 38, ehw145.	2.2	220
41	Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. European Heart Journal, 2016, 37, 1789-1798.	2.2	210
42	Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2013, 98, 7-27.	3.8	209
43	Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease. British Journal of Pharmacology, 2014, 171, 1890-1906.	5.4	206
44	Preconditioning protects by inhibiting the mitochondrial permeability transition. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H841-H849.	3.2	205
45	The therapeutic potential of ischemic conditioning: an update. Nature Reviews Cardiology, 2011, 8, 619-629.	13.7	205
46	Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 178-188.	2.9	199
47	The neural and humoral pathways in remote limb ischemic preconditioning. Basic Research in Cardiology, 2010, 105, 651-655.	5.9	197
48	Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Research in Cardiology, 2008, 103, 274-284.	5.9	185
49	Reducing myocardial infarct size: challenges and future opportunities. Heart, 2016, 102, 341-348.	2.9	185
50	Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. International Journal of Biochemistry and Cell Biology, 2006, 38, 414-419.	2.8	167
51	Reperfusion Injury Salvage Kinase and Survivor Activating Factor Enhancement Prosurvival Signaling Pathways in Ischemic Postconditioning: Two Sides of the Same Coin. Antioxidants and Redox Signaling, 2011, 14, 893-907.	5.4	166
52	Statins and cardioprotection â€" More than just lipid lowering?. , 2009, 122, 30-43.		164
53	Mitochondrial Dynamics in Cardiovascular Health and Disease. Antioxidants and Redox Signaling, 2013, 19, 400-414.	5.4	164
54	New horizons for newborn brain protection: enhancing endogenous neuroprotection. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015, 100, F541-F552.	2.8	164

#	Article	IF	Citations
55	Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. European Heart Journal Cardiovascular Imaging, 2012, 13, 819-826.	1.2	161
56	Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. Heart, 2015, 101, 185-192.	2.9	160
57	Contrast-induced nephropathy following angiography and cardiac interventions. Heart, 2016, 102, 638-648.	2.9	160
58	Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. European Heart Journal, 2011, 32, 23-31.	2.2	157
59	Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovascular Research, 2004, 63, 305-312.	3.8	155
60	The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovascular Research, 2019, 115, 1143-1155.	3.8	151
61	Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction. Cell Death and Disease, 2016, 7, e2238-e2238.	6.3	150
62	Mitochondria in acute myocardial infarction and cardioprotection. EBioMedicine, 2020, 57, 102884.	6.1	148
63	ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovascular Research, 2014, 104, 399-411.	3.8	143
64	Optimized Treatment of ST-Elevation Myocardial Infarction. Circulation Research, 2019, 125, 245-258.	4.5	140
65	HIF-1 reduces ischaemiaâ€“reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovascular Research, 2014, 104, 24-36.	3.8	136
66	Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H237-H242.	3.2	135
67	The Second Window of Preconditioning (SWOP) Where Are We Now?. Cardiovascular Drugs and Therapy, 2010, 24, 235-254.	2.6	133
68	Cardiovascular Magnetic Resonance in Acute ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2018, 137, 1949-1964.	1.6	128
69	Targeting Myocardial Reperfusion Injury â€" The Search Continues. New England Journal of Medicine, 2015, 373, 1073-1075.	27.0	127
70	The novel adipocytokine visfatin exerts direct cardioprotective effects. Journal of Cellular and Molecular Medicine, 2008, 12, 1395-1403.	3.6	125
71	Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovascular Research, 2019, 115, 1117-1130.	3.8	125
72	Cardioprotection during cardiac surgery. Cardiovascular Research, 2012, 94, 253-265.	3.8	123

#	Article	IF	Citations
73	Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segmentâ€“Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	120
74	ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. European Heart Journal, 2017, 38, 2392-2411.	2.2	118
75	Mitochondrial fusion and fission proteins as novel therapeutic targets for treating cardiovascular disease. European Journal of Pharmacology, 2015, 763, 104-114.	3.5	114
76	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 725-736.	3.8	114
77	Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. British Journal of Pharmacology, 2012, 165, 1235-1245.	5.4	113
78	Cardiac preconditioning for ischaemia: lost in translation. DMM Disease Models and Mechanisms, 2010, 3, 35-38.	2.4	105
79	Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Research in Cardiology, 2007, 102, 453-459.	5.9	103
80	Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Research in Cardiology, 2015, 110, 453.	5.9	103
81	Effect of Remote Ischemic Preconditioning on Acute Kidney Injury in Nondiabetic Patients Undergoing Coronary Artery Bypass Graft Surgery: A Secondary Analysis of 2 Small Randomized Trials. American Journal of Kidney Diseases, 2010, 56, 1043-1049.	1.9	102
82	Loss of PINK1 Increases the Heart's Vulnerability to Ischemia-Reperfusion Injury. PLoS ONE, 2013, 8, e62400.	2.5	99
83	Hypoxia-inducible factor as a therapeutic target for cardioprotection. , 2012, 136, 69-81.		97
84	Time to Take Myocardial Reperfusion Injury Seriously. New England Journal of Medicine, 2008, 359, 518-520.	27.0	95
85	Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1265-H1270.	3.2	94
86	Realizing the clinical potential of ischemic preconditioning and postconditioning. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 568-575.	3.3	92
87	Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clinical Research in Cardiology, 2012, 101, 339-348.	3.3	91
88	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. Cardiovascular Research, 2019, 115, 488-500.	3.8	90
89	Coâ€morbidities and coâ€medications as confounders of cardioprotectionâ€"Does it matter in the clinical setting?. British Journal of Pharmacology, 2020, 177, 5252-5269.	5.4	90
90	Cardioprotective growth factors. Cardiovascular Research, 2009, 83, 179-194.	3.8	87

#	Article	IF	Citations
91	Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning. Cardiovascular Research, 2010, 88, 67-74.	3.8	86
92	Chronic Metformin Associated Cardioprotection Against Infarction: Not Just a Glucose Lowering Phenomenon. Cardiovascular Drugs and Therapy, 2013, 27, 5-16.	2.6	86
93	Protection of organs other than the heart by remote ischemic conditioning. Journal of Cardiovascular Medicine, 2013, 14, 193-205.	1.5	86
94	Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Research in Cardiology, 2016, 111, 50.	5.9	84
95	Hypoxia signaling controls postnatal changes in cardiac mitochondrial morphology and function. Journal of Molecular and Cellular Cardiology, 2014, 74, 340-352.	1.9	82
96	Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovascular Diabetology, 2013, 12, 154.	6.8	81
97	Investigating the Signal Transduction Pathways Underlying Remote Ischemic Conditioning in the Porcine Heart. Cardiovascular Drugs and Therapy, 2012, 26, 87-93.	2.6	80
98	Non-coding RNAs as therapeutic targets for preventing myocardial ischemia-reperfusion injury. Expert Opinion on Therapeutic Targets, 2018, 22, 247-261.	3.4	80
99	Signalling pathways in ischaemic postconditioning. Thrombosis and Haemostasis, 2009, 101, 626-634.	3.4	79
100	RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-Î± in cardiac ischaemia/reperfusion injury. Thrombosis and Haemostasis, 2014, 112, 1110-1119.	3.4	79
101	Myocardial Infarct Size by CMR in ClinicalÂCardioprotection Studies. JACC: Cardiovascular Imaging, 2017, 10, 230-240.	5.3	78
102	Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis. Journal of the American College of Cardiology, 2015, 65, 2764-2765.	2.8	77
103	Myocardial postconditioning: reperfusion injury revisited. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H2-H7.	3.2	76
104	Akt protects the heart against ischaemia-reperfusion injury by modulating mitochondrial morphology. Thrombosis and Haemostasis, 2015, 113, 513-521.	3.4	76
105	Mitochondrial-Shaping Proteins in Cardiac Health and Disease â€“ the Long and the Short of It!. Cardiovascular Drugs and Therapy, 2017, 31, 87-107.	2.6	75
106	Ischemic preconditioning targets the reperfusion phase. Basic Research in Cardiology, 2007, 102, 445-452.	5.9	74
107	Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovascular Research, 2013, 99, 694-704.	3.8	74
108	Cardioprotection Techniques: Preconditioning, Postconditioning and Remote Con-ditioning (Basic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	74

#	Article	IF	Citations
109	IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Research in Cardiology, 2021, 116, 52.	5.9	73
110	Preconditioning the diabetic human myocardium. Journal of Cellular and Molecular Medicine, 2010, 14, 1740-1746.	3.6	70
111	T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 73.	3.3	70
112	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	2.2	69
113	Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor. Journal of Cardiovascular Pharmacology, 2009, 53, 373-378.	1.9	68
114	Effect of hyperglycaemia and diabetes on acute myocardial ischaemiaâ€"reperfusion injury and cardioprotection by ischaemic conditioning protocols. British Journal of Pharmacology, 2020, 177, 5312-5335.	5.4	68
115	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. European Heart Journal, 2021, 42, 323-334.	2.2	68
116	Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart, 2011, 97, 1560-1565.	2.9	66
117	Novel therapeutic strategies for cardioprotection. , 2014, 144, 60-70.		64
118	Targeting mitochondrial fusion and fission proteins for cardioprotection. Journal of Cellular and Molecular Medicine, 2020, 24, 6571-6585.	3.6	63
119	Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials. International Journal of Cardiology, 2016, 202, 228-237.	1.7	62
120	Erythropoietin: ready for prime-time cardioprotection. Trends in Pharmacological Sciences, 2008, 29, 258-267.	8.7	61
121	Role of the <scp>MPTP</scp> in conditioning the heart â€" translatability and mechanism. British Journal of Pharmacology, 2015, 172, 2074-2084.	5.4	61
122	Mitochondrial fission protein Drp1 inhibition promotes cardiac mesodermal differentiation of human pluripotent stem cells. Cell Death Discovery, 2018, 4, 39.	4.7	61
123	Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective. Journal of the American Heart Association, 2018, 7, e009949.	3.7	61
124	Oxidative stress in cardiac hypertrophy: From molecular mechanisms to novel therapeutic targets. Free Radical Biology and Medicine, 2021, 166, 297-312.	2.9	60
125	Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal, 2015, 36, 1846-8.	2.2	59
126	Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. Journal of Cellular and Molecular Medicine, 2011, 15, 2443-2451.	3.6	58

#	Article	IF	Citations
127	Contrastâ€induced acute kidney injury following <scp>PCI</scp>. European Journal of Clinical Investigation, 2013, 43, 483-490.	3.4	56
128	Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 26.	3.3	55
129	Quantifying the Area at Risk in Reperfused ST-Segmentâ€"Elevation Myocardial Infarction Patients Using Hybrid Cardiac Positron Emission Tomographyâ€"Magnetic Resonance Imaging. Circulation: Cardiovascular Imaging, 2016, 9, e003900.	2.6	54
130	Remote ischaemic conditioning: cardiac protection from afar. Anaesthesia, 2015, 70, 732-748.	3.8	53
131	Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 367-385.	3.8	53
132	AMP-activated protein kinase: A remarkable contributor to preserve a healthy heart against ROS injury. Free Radical Biology and Medicine, 2021, 166, 238-254.	2.9	52
133	FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 387-401.	2.4	51
134	Targeting Mitochondrial Fission Using Mdivi-1 in A Clinically Relevant Large Animal Model of Acute Myocardial Infarction: A Pilot Study. International Journal of Molecular Sciences, 2019, 20, 3972.	4.1	50
135	The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire. Current Medicinal Chemistry, 2018, 25, 1275-1293.	2.4	50
136	The Diabetic Heart: Too Sweet for Its Own Good?. Cardiology Research and Practice, 2012, 2012, 1-15.	1.1	48
137	Parkinson's disease proteins: Novel mitochondrial targets for cardioprotection. , 2015, 156, 34-43.		48
138	Mitochondrial ion channels as targets for cardioprotection. Journal of Cellular and Molecular Medicine, 2020, 24, 7102-7114.	3.6	48
139	Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure. Free Radical Biology and Medicine, 2021, 163, 325-343.	2.9	48
140	Role of Macrophages in Cardioprotection. International Journal of Molecular Sciences, 2019, 20, 2474.	4.1	47
141	Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Postâ€"Reperfused STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	46
142	Ageing, sex, and cardioprotection. British Journal of Pharmacology, 2020, 177, 5270-5286.	5.4	46
143	Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segmentâ€"Elevation Myocardial Infarction Patients. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	45
144	Intercellular Communication in the Heart: Therapeutic Opportunities for Cardiac Ischemia. Trends in Molecular Medicine, 2021, 27, 248-262.	6.7	45

#	Article	IF	Citations
145	The divergent roles of protein kinase C epsilon and delta in simulated ischaemiaâ€“reperfusion injury in human myocardium. Journal of Molecular and Cellular Cardiology, 2009, 46, 758-764.	1.9	43
146	Long-term Prognostic Value of Cardiac MRI Left Atrial Strain in ST-Segment Elevation Myocardial Infarction. Radiology, 2020, 296, 299-309.	7.3	43
147	Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction. Cardiovascular Research, 2021, 117, 918-929.	3.8	43
148	Remote Ischemic Conditioning: A Clinical Trialâ€™s Update. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 304-312.	2.0	42
149	Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection. Antioxidants and Redox Signaling, 2020, 32, 1135-1149.	5.4	42
150	From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on â€œNew frontiers in cardiovascular researchâ€. Basic Research in Cardiology, 2016, 111, 69.	5.9	41
151	Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 57.	3.3	41
152	Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction. Journal of Nuclear Cardiology, 2018, 25, 2001-2011.	2.1	41
153	The Role of O-GlcNAcylation for Protection against Ischemia-Reperfusion Injury. International Journal of Molecular Sciences, 2019, 20, 404.	4.1	40
154	â€˜Conditioningâ€™ the heart during surgery. European Journal of Cardio-thoracic Surgery, 2009, 35, 977-987.	1.4	39
155	Diabetic Cardiomyopathy and Ischemic Heart Disease: Prevention and Therapy by Exercise and Conditioning. International Journal of Molecular Sciences, 2020, 21, 2896.	4.1	38
156	Fatty acid metabolism driven mitochondrial bioenergetics promotes advanced developmental phenotypes in human induced pluripotent stem cell derived cardiomyocytes. International Journal of Cardiology, 2018, 272, 288-297.	1.7	37
157	Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection. Cardiovascular Research, 2019, 115, 1167-1177.	3.8	37
158	Mitochondrial Dynamics as a Therapeutic Target for Treating Cardiac Diseases. Handbook of Experimental Pharmacology, 2016, 240, 251-279.	1.8	36
159	Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 91.	3.3	36
160	Timeâ€Stratified Case Crossover Study of the Association of Outdoor Ambient Air Pollution With the Risk of Acute Myocardial Infarction in the Context of Seasonal Exposure to the Southeast Asian Haze Problem. Journal of the American Heart Association, 2019, 8, e011272.	3.7	36
161	Signalling pathways in ischaemic postconditioning. Thrombosis and Haemostasis, 2009, 101, 626-34.	3.4	36
162	Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current Opinion in Cardiology, 2009, 24, 473-482.	1.8	34

#	Article	IF	Citations
163	Targeting mitochondria for cardioprotection: examining the benefit for patients. Future Cardiology, 2014, 10, 255-272.	1.2	34
164	GLP-1 Therapy. Circulation: Heart Failure, 2008, 1, 147-149.	3.9	33
165	Cardiac troponins and volatile anaesthetics in coronary artery bypass graft surgery. European Journal of Anaesthesiology, 2016, 33, 396-407.	1.7	33
166	Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Scientific Reports, 2017, 7, 43958.	3.3	33
167	Sevoflurane, Propofol and Carvedilol Block Myocardial Protection by Limb Remote Ischemic Preconditioning. International Journal of Molecular Sciences, 2019, 20, 269.	4.1	33
168	The Akt1 isoform is an essential mediator of ischaemic preconditioning. Journal of Cellular and Molecular Medicine, 2012, 16, 1739-1749.	3.6	32
169	Glimepiride Treatment Facilitates Ischemic Preconditioning in the Diabetic Heart. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 263-269.	2.0	32
170	Circadian variation in acute myocardial infarct size assessed by cardiovascular magnetic resonance in reperfused STEMI patients. International Journal of Cardiology, 2017, 230, 149-154.	1.7	31
171	Nitroglycerine limits infarct size through S-nitrosation of cyclophilin D: a novel mechanism for an old drug. Cardiovascular Research, 2019, 115, 625-636.	3.8	31
172	A future for remote ischaemic conditioning in high-risk patients. Basic Research in Cardiology, 2020, 115, 35.	5.9	31
173	Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. Cardiovascular Research, 2022, 118, 282-294.	3.8	31
174	Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERICâ€ONC Studyâ€"A Singleâ€Center, Blinded, Randomized Controlled Trial. Clinical Cardiology, 2016, 39, 72-82.	1.8	29
175	Rapid assessment of myocardial infarct size in rodents using multi-slice inversion recovery late gadolinium enhancement CMR at 9.4T. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 44.	3.3	28
176	Effect of Ischemic Preconditioning and Postconditioning on Exosome-Rich Fraction microRNA Levels, in Relation with Electrophysiological Parameters and Ventricular Arrhythmia in Experimental Closed-Chest Reperfused Myocardial Infarction. International Journal of Molecular Sciences, 2019, 20, 2140.	4.1	28
177	Neutrophils Modulate Fibroblast Function and Promote Healing and Scar Formation after Murine Myocardial Infarction â€. International Journal of Molecular Sciences, 2020, 21, 3685.	4.1	28
178	An automated workflow for segmenting single adult cardiac cells from large-volume serial block-face scanning electron microscopy data. Journal of Structural Biology, 2018, 202, 275-285.	2.8	27
179	Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes. Cardiovascular Research, 2022, 118, 517-530.	3.8	27
180	Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients. Cardiovascular Diabetology, 2021, 20, 211.	6.8	27

#	Article	IF	Citations
181	Index of Microvascular Resistance and Microvascular Obstruction in Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 2172-2174.	2.9	26
182	The cardioprotective effects of mineralocorticoid receptor antagonists. , 2014, 142, 72-87.		25
183	Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI). Basic Research in Cardiology, 2021, 116, 4.	5.9	25
184	The evolving story of "conditioning" to protect against acute myocardial ischaemia-reperfusion injury. Heart, 2007, 93, 649-651.	2.9	24
185	Immediate remote ischemic postconditioning after hypoxia ischemia in piglets protects cerebral white matter but not grey matter. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1396-1411.	4.3	24
186	Diagnostic performance of <i>T</i>₁ and <i>T</i>₂ mapping to detect intramyocardial hemorrhage in reperfused STâ€segment elevation myocardial infarction (STEMI) patients. Journal of Magnetic Resonance Imaging, 2017, 46, 877-886.	3.4	24
187	Why did remote ischaemic conditioning not improve clinical outcomes in acute myocardial infarction in the CONDI-2/ERIC-PPCI trial?. Cardiovascular Research, 2019, 115, e161-e163.	3.8	24
188	Vascular conditioning prevents adverse left ventricular remodelling after acute myocardial infarction: a randomised remote conditioning study. Basic Research in Cardiology, 2021, 116, 9.	5.9	24
189	Effects of delayed remote ischemic preconditioning on peri-operative myocardial injury in patients undergoing cardiac surgery â€" A randomized controlled trial. International Journal of Cardiology, 2017, 227, 511-515.	1.7	23
190	Ischaemic conditioning: are we there yet?. Heart, 2015, 101, 1067-1077.	2.9	22
191	Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. Basic Research in Cardiology, 2011, 106, 1387-1395.	5.9	21
192	Mitochondrial respiratory inhibition by 2,3-butanedione monoxime (BDM): implications for culturing isolated mouse ventricular cardiomyocytes. Physiological Reports, 2016, 4, e12606.	1.7	21
193	Unique morphological characteristics of mitochondrial subtypes in the heart: the effect of ischemia and ischemic preconditioning. Discoveries, 2017, 5, e71.	2.3	21
194	Periprocedural elevated myocardial biomarkers and clinical outcomes following elective percutaneous coronary intervention: a comprehensive dose-response meta-analysis of 44,972 patients from 24 prospective studies. EuroIntervention, 2020, 15, 1444-1450.	3.2	20
195	Drug discovery possibilities from visfatin cardioprotection?. Current Opinion in Pharmacology, 2009, 9, 202-207.	3.5	19
196	Age and Surgical Complexity impact on Renoprotection by Remote Ischemic Preconditioning during Adult Cardiac Surgery: A Meta analysis. Scientific Reports, 2017, 7, 215.	3.3	19
197	Association between smoking status and outcomes in myocardial infarction patients undergoing percutaneous coronary intervention. Scientific Reports, 2021, 11, 6466.	3.3	19
198	MiD49 and MiD51: New mediators of mitochondrial fission and novel targets for cardioprotection. Conditioning Medicine, 2018, 1, 239-246.	1.3	19

#	Article	IF	Citations
199	A retrospective analysis of myocardial preservation techniques during coronary artery bypass graft surgery: are we protecting the heart?. Journal of Cardiothoracic Surgery, 2014, 9, 184.	1.1	18
200	Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance. Open Heart, 2016, 3, e000535.	2.3	18
201	Combination Therapy to Target Reperfusion Injury After ST-Segmentâ€“Elevation Myocardial Infarction. Circulation, 2017, 136, 904-906.	1.6	18
202	Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. American Heart Journal, 2019, 211, 60-67.	2.7	18
203	The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry. Scientific Reports, 2020, 10, 6799.	3.3	18
204	OPA1 in Cardiovascular Health and Disease. Current Drug Targets, 2015, 16, 912-920.	2.1	18
205	Sustainable low-field cardiovascular magnetic resonance in changing healthcare systems. European Heart Journal Cardiovascular Imaging, 2022, 23, e246-e260.	1.2	17
206	Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality. Heart, 2018, 104, 313-317.	2.9	16
207	Air pollution in relation to very short-term risk of ST-segment elevation myocardial infarction: Case-crossover analysis of SWEDEHEART. International Journal of Cardiology, 2019, 275, 26-30.	1.7	16
208	Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction. Basic Research in Cardiology, 2021, 116, 36.	5.9	16
209	â€œConditional Conditioningâ€•in cardiac bypass surgery. Basic Research in Cardiology, 2012, 107, 258.	5.9	15
210	Independent Predictors of Cardiac Mortality and Hospitalization for Heart Failure in a Multi-Ethnic Asian ST-segment Elevation Myocardial Infarction Population Treated by Primary Percutaneous Coronary Intervention. Scientific Reports, 2019, 9, 10072.	3.3	15
211	Platelet inhibition to target reperfusion injury trial: Rationale and study design. Clinical Cardiology, 2019, 42, 5-12.	1.8	15
212	Aprotininâ€”still courting controversy. Lancet, The, 2008, 371, 449-450.	13.7	14
213	The shape of things to come: mitochondrial fusion and fission in the adult heart. Cardiovascular Research, 2012, 94, 391-392.	3.8	14
214	Imaging the Myocardial Microcirculation Post-Myocardial Infarction. Current Heart Failure Reports, 2012, 9, 282-292.	3.3	14
215	Renoprotection by remote ischemic conditioning during elective coronary revascularization: A systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology, 2016, 222, 295-302.	1.7	14
216	Modulating NAD+ metabolism to prevent acute kidney injury. Nature Medicine, 2018, 24, 1306-1307.	30.7	14

#	Article	IF	Citations
217	Acute administration of the olive constituent, oleuropein, combined with ischemic postconditioning increases myocardial protection by modulating oxidative defense. Free Radical Biology and Medicine, 2021, 166, 18-32.	2.9	14
218	Not just the powerhouse of the cell: emerging roles for mitochondria in the heart. Cardiovascular Research, 2010, 88, 5-6.	3.8	13
219	The Effect of Remote Ischemic Conditioning and Glyceryl Trinitrate on Perioperative Myocardial Injury in Cardiac Bypass Surgery Patients: Rationale and Design of the <scp>ERICâ€GTN</scp> Study. Clinical Cardiology, 2015, 38, 641-646.	1.8	13
220	Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial. Cardiovascular Research, 2021, 117, 623-634.	3.8	13
221	Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. Basic Research in Cardiology, 2021, 116, 59.	5.9	13
222	Remote ischemic conditioning in ST-segment elevation myocardial infarction - an update. Conditioning Medicine, 2018, 1, 13-22.	1.3	13
223	Conditioning the heart to prevent myocardial reperfusion injury during PPCI. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 13-32.	1.0	12
224	In Vitro Culture of Epicardial Cells From Mouse Embryonic Heart. Journal of Visualized Experiments, 2016, , .	0.3	12
225	Nanoparticle delivery of mitoprotective agents to target ischemic heart disease. Future Cardiology, 2017, 13, 195-198.	1.2	12
226	Remote Ischemic Conditioning in Emergency Medicineâ€"Clinical Frontiers and Research Opportunities. Shock, 2020, 53, 269-276.	2.1	12
227	Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization. Scientific Reports, 2020, 10, 15184.	3.3	12
228	Gender Differences in Native Myocardial T1 in a Healthy Chinese Volunteer Cohort. Cardiovascular Imaging Asia, 2017, 1, 110.	0.1	12
229	Comparison of Mortality Outcomes in Acute Myocardial Infarction Patients With or Without Standard Modifiable Cardiovascular Risk Factors. Frontiers in Cardiovascular Medicine, 2022, 9, 876465.	2.4	12
230	Failure of the Adipocytokine, Resistin, to Protect the Heart From Ischemia-Reperfusion Injury. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 63-71.	2.0	11
231	Taking lizard saliva to heart. European Heart Journal, 2012, 33, 1426-1430.	2.2	11
232	Assessing the effects of mitofusin 2 deficiency in the adult heart using 3D electron tomography. Physiological Reports, 2017, 5, e13437.	1.7	11
233	Quantifying the area-at-risk of myocardial infarction in-vivo using arterial spin labeling cardiac magnetic resonance. Scientific Reports, 2017, 7, 2271.	3.3	11
234	Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. Cardiovascular Research, 2017, 113, 1418-1419.	3.8	11

#	Article	IF	Citations
235	Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction. Scientific Reports, 2017, 7, 14676.	3.3	11
236	Effect of remote ischemic preConditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial. Hpb, 2020, 22, 1250-1257.	0.3	11
237	Phosphatidylserine Supplementation as a Novel Strategy for Reducing Myocardial Infarct Size and Preventing Adverse Left Ventricular Remodeling. International Journal of Molecular Sciences, 2021, 22, 4401.	4.1	11
238	AÂneutralizing IL-11 antibody reduces vessel hyperplasia in a mouse carotid artery wire injury model. Scientific Reports, 2021, 11, 20674.	3.3	11
239	Mineralocorticoid Receptor Antagonist Pretreatment to <scp>MINIMISE</scp> Reperfusion Injury After <scp>ST</scp>â€Elevation Myocardial Infarction (The <scp>MINIMISE STEMI</scp> Trial): Rationale and Study Design. Clinical Cardiology, 2015, 38, 259-266.	1.8	10
240	Is there a role for ischaemic conditioning in cardiac surgery?. F1000Research, 2017, 6, 563.	1.6	10
241	Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. Cardiovascular Research, 2021, 117, 694-711.	3.8	10
242	Circadian rhythms in ischaemic heart disease: key aspects for preclinical and translational research: position paper of the ESC working group on cellular biology of the heart. Cardiovascular Research, 2021, , .	3.8	10
243	Myocardial protection: is primary PCI enough?. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 12-13.	3.3	9
244	Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI. Journal of the American College of Cardiology, 2018, 71, 2856-2858.	2.8	9
245	Translating Cardioprotection for Patient Benefit. Journal of the American College of Cardiology, 2019, 73, 2001-2003.	2.8	9
246	Cell Membrane Repair as a Mechanism for Ischemic Preconditioning?. Circulation, 2010, 121, 2547-2549.	1.6	8
247	Preconditioning Shields Against Vascular Events in Surgery (SAVES), a multicentre feasibility trial of preconditioning against adverse events in major vascular surgery: study protocol for a randomised control trial. Trials, 2015, 16, 185.	1.6	8
248	Risk factors, coâ€morbidities, and coâ€medications in cardioprotection: Importance for translation. British Journal of Pharmacology, 2020, 177, 5249-5251.	5.4	8
249	ObstrucciÃ³n microvascular: el azote de la reperfusiÃ³n miocÃ¡rdica. Revista Espanola De Cardiologia, 2015, 68, 919-920.	1.2	7
250	Chronic remote ischemic conditioning for cardiovascular protection. Conditioning Medicine, 2019, 2, 164-169.	1.3	7
251	Adenosine-Induced Second Window of Protection is Mediated by Inhibition of Mitochondrial Permeability Transition Pore Opening at the Time of Reperfusion. Cardiovascular Drugs and Therapy, 2004, 18, 79-80.	2.6	6
252	Premature Meta-Analysis of Remote Ischemic Preconditioning. American Journal of Cardiology, 2009, 103, 893-894.	1.6	6

#	Article	IF	Citations
253	The Mitochondrial Permeability Transition Pore as a Target for Cardioprotection in Hypertrophic Cardiomyopathy. Cardiovascular Drugs and Therapy, 2013, 27, 235-237.	2.6	6
254	Atrial Fibrillation in the Intensive Care Setting. Journal of the Intensive Care Society, 2013, 14, 141-149.	2.2	6
255	A simple technique to measure TAPSE and MAPSE on CMR and normal values. Journal of Cardiovascular Magnetic Resonance, 2014, 16, P22.	3.3	6
256	Full left ventricular coverage is essential for the accurate quantification of the area-at-risk by T1 and T2 mapping. Scientific Reports, 2017, 7, 4871.	3.3	6
257	Shining the spotlight on cardioprotection: beyond the cardiomyocyte. Cardiovascular Research, 2019, 115, 1115-1116.	3.8	6
258	Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial. Efficacy and Mechanism Evaluation, 2016, 3, 1-58.	0.7	6
259	Contrave^{TM}: novel treatment for obesity. Clinical Lipidology, 2009, 4, 279-285.	0.4	5
260	Dissociating HDL cholesterol from cardiovascular risk. Lancet, The, 2010, 376, 305-306.	13.7	5
261	Infective endocarditis: An intensive care perspective. Trends in Anaesthesia and Critical Care, 2012, 2, 36-41.	0.9	5
262	Microvascular Obstruction: The Bane of Myocardial Reperfusion. Revista Espanola De Cardiologia (English Ed), 2015, 68, 919-920.	0.6	5
263	T and Small Protrusion (TAP) vs Double-Kissing Crush Technique: Insights From In Vitro Models. Cardiovascular Revascularization Medicine, 2021, 24, 11-17.	0.8	5
264	Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion. Oncotarget, 2017, 8, 67227-67240.	1.8	5
265	Lipid profiles and outcomes of patients with prior cancer and subsequent myocardial infarction or stroke. Scientific Reports, 2021, 11, 21167.	3.3	5
266	Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial. Cardiovascular Drugs and Therapy, 2023, 37, 299-305.	2.6	5
267	Negative interaction between nitrates and remote ischemic preconditioning in patients undergoing cardiac surgery: the ERIC-GTN and ERICCA studies. Basic Research in Cardiology, 2022, 117, .	5.9	5
268	Postconditioning does not protect the diabetic heart. Journal of Molecular and Cellular Cardiology, 2006, 40, 958.	1.9	4
269	The Full Width Half Maximum technique is superior for LGE quantification regardless of its aetiology. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	4
270	Surfing on the Cardiovascular Frontier Wave. Thrombosis and Haemostasis, 2015, 113, 439-440.	3.4	4

#	Article	IF	Citations
271	The metabolic syndrome raises the threshold for cardioprotection. Journal of Molecular and Cellular Cardiology, 2007, 42, S185.	1.9	3
272	Mapping Myocardial Salvage Index by Extracellular Volume Fraction. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	3
273	Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality. American Heart Journal, 2020, 224, 1-9.	2.7	3
274	Repeated Remote Ischemic Conditioning Protects Against Doxorubicin Cardiotoxicity. JACC: CardioOncology, 2020, 2, 53-55.	4.0	3
275	Special issue â€œImplications of oxidative stress and redox biochemistry for heart disease and cardioprotection - The EU-CARDIOPROTECTION COST action (CA16225)â€• Free Radical Biology and Medicine, 2021, 171, 314-318.	2.9	3
276	Strategies for Reducing Myocardial Infarct Size Following STEMI. , 2018, , 307-322.		3
277	INDUCED PLURIPOTENT STEM CELLS FOR MODELLING ENERGETIC ALTERATIONS IN HYPERTROPHIC CARDIOMYOPATHY. Conditioning Medicine, 2019, 2, 142-151.	1.3	3
278	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. Conditioning Medicine, 2020, 3, 82-97.	1.3	3
279	Cardiovascular assessment for noncardiac surgery. Current Anaesthesia and Critical Care, 2005, 16, 263-269.	0.3	2
280	Glimepiride reduces the threshold for ischemic preconditioning in the diabetic heart. Journal of Molecular and Cellular Cardiology, 2007, 42, S177.	1.9	2
281	Platelet inhibitors influence cardioprotection: importance in preclinical study design: reply. Cardiovascular Research, 2015, 106, 8-8.	3.8	2
282	Remote Ischemic Preconditioning: Would You Give Your Right Arm to Protect Your Kidneys?. American Journal of Kidney Diseases, 2016, 67, 16-19.	1.9	2
283	Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1935-1940.	1.6	2
284	Cardioprotective effect of combination therapy by mild hypothermia and local or remote ischemic preconditioning in isolated rat hearts. Scientific Reports, 2021, 11, 265.	3.3	2
285	Mitochondrial shaping proteins as novel treatment targets for cardiomyopathies. Conditioning Medicine, 2020, 3, 216-226.	1.3	2
286	Appropriate criteria for the definition of Type 4a MI. European Heart Journal, 2021, , .	2.2	2
287	Inhibiting mitochondrial permeability transition pore opening: A new paradigm in myocardial preconditioning?. Journal of Molecular and Cellular Cardiology, 2002, 34, A28.	1.9	1
288	Echocardiography and the critically ill patient. Current Anaesthesia and Critical Care, 2006, 17, 237-244.	0.3	1

#	Article	IF	Citations
289	Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Journal of Molecular and Cellular Cardiology, 2007, 42, S171.	1.9	1
290	Metformin cardioprotects the diabetic heart by inhibiting mPTP opening via the risk pathway. Journal of Molecular and Cellular Cardiology, 2007, 42, S217.	1.9	1
291	Limitation of myocardial ischemia-reperfusion injury in clinical practice. Current Opinion in Lipidology, 2012, 23, 588-590.	2.7	1
292	Predicting peri-procedural myocardial infarction during PCI. Heart, 2012, 98, 1471-1472.	2.9	1
293	Cardiogenic Shock and the ICU Patient. Journal of the Intensive Care Society, 2013, 14, 235-243.	2.2	1
294	CMR detects a reduction in infarct size and myocardial edema when primary PCI is augmented by Remote Ischemic Conditioning. A randomized trial. Journal of Cardiovascular Magnetic Resonance, 2014, 16, P208.	3.3	1
295	Hybrid PET/MR metabolic imaging of the reperfused infarct - new biology, future directions. Journal of Cardiovascular Magnetic Resonance, 2015, 17, O41.	3.3	1
296	Letter by Bulluck and Hausenloy Regarding Article, â€œAir Versus Oxygen in ST-Segmentâ€“Elevation Myocardial Infarctionâ€ Circulation, 2016, 133, e28.	1.6	1
297	Reply to â€œCircadian variation in acute myocardial infarction size: Likely involvement of the melatonin and suprachiasmatic nucleiâ€ International Journal of Cardiology, 2017, 235, 192-193.	1.7	1
298	Risk Stratification by Cardiovascular Magnetic Resonance After Reperfused ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2018, 11, 826-828.	5.3	1
299	Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients. Scientific Reports, 2019, 9, 9056.	3.3	1
300	Feasibility to Perform T₂* Mapping Postcontrast Administration in Reperfused STEMI Patients for the Detection of Intramyocardial Hemorrhage. Journal of Magnetic Resonance Imaging, 2020, 51, 644-645.	3.4	1
301	Editorial: New Advances in RNA Targeting. Frontiers in Pharmacology, 2020, 11, 468.	3.5	1
302	Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?. Conditioning Medicine, 2019, 2, 204-212.	1.3	1
303	Extracellular vesicles - mediating and delivering cardioprotection in acute myocardial infarction and heart failure. Conditioning Medicine, 2020, 3, 227-238.	1.3	1
304	Prognostically relevant cardiac troponin elevations with percutaneous coronary interventions. European Heart Journal, 2021, , .	2.2	1
305	Reperfusion signaling in preconditioned hearts: Role for Pkc, The Mkatp channel, oxidative stress and transient acidosis. Journal of Molecular and Cellular Cardiology, 2007, 42, S173.	1.9	0
306	Transient upper arm ischemia reduces myocardial injury in patients undergoing cardiac bypass surgery. Journal of Molecular and Cellular Cardiology, 2007, 42, S181.	1.9	0

#	Article	IF	Citations
307	Cardioprotective actions of the novel adipocytokine visfatin. Journal of Molecular and Cellular Cardiology, 2007, 42, S216-S217.	1.9	0
308	Over-expression of the cardioprotective kinase Akt modulates mitochondrial morphology. Journal of Molecular and Cellular Cardiology, 2008, 44, 726.	1.9	0
309	The adipocytokine, resistin, is not cardioprotective despite activating components of the risk pathway. Journal of Molecular and Cellular Cardiology, 2008, 44, 728.	1.9	0
310	Can high-dose atorvastatin provide cardioprotection during coronary artery bypass surgery?. Journal of Molecular and Cellular Cardiology, 2008, 44, 729.	1.9	0
311	The human diabetic myocardium has a higher threshold for protection against simulated ischaemiaâ€"reperfusion injury. Journal of Molecular and Cellular Cardiology, 2008, 44, 731-732.	1.9	0
312	Protein kinase C delta and epsilon isoforms have divergent roles in simulated ischaemiaâ€"reperfusion injury in human atrial muscle. Journal of Molecular and Cellular Cardiology, 2008, 44, 732.	1.9	0
313	Remote ischaemic preconditioning confers cardioprotection over and above cardioplegia during cardiac surgery. Journal of Molecular and Cellular Cardiology, 2008, 44, 772-773.	1.9	0
314	Urinary Trypsin Inhibition: Cardioprotection via the Reperfusion Injury Salvage Kinase Pathway. Cardiology, 2009, 114, 261-263.	1.4	0
315	Corrigendum to â€œâ€˜Conditioningâ€™ the heart during surgeryâ€•[Eur. J. Cardiothorac. Surg. 35 (6) (2009) 977â€"987]. European Journal of Cardio-thoracic Surgery, 2009, 36, 608-608.	1.4	0
316	Reply to Landoni et al.. European Journal of Cardio-thoracic Surgery, 2010, 37, 983-983.	1.4	0
317	T1 mapping for myocardial extracellular volume measurement by cardiovascular magnetic resonance: bolus only vs primed infusion technique. Journal of Cardiovascular Magnetic Resonance, 2013, 15, O14.	3.3	0
318	Variable myocardial interstitial expansion by T1 mapping within LGE area in infarction and hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2013, 15, P168.	3.3	0
319	Coronary Plaque Composition and Post-PCI Complications in NSTEMI. JACC: Cardiovascular Imaging, 2013, 6, 1349-1350.	5.3	0
320	Response:. Journal of the Intensive Care Society, 2013, 14, 277-277.	2.2	0
321	THE ADULT MURINE HEART IS PROTECTED AGAINST ISCHEMIA-REPERFUSION INJURY IN THE ABSENCE OF BOTH MITOFUSIN (MFN) PROTEINS. Heart, 2014, 100, A22.3-A23.	2.9	0
322	THE DIFFERENTIAL EFFECTS OF SIRTUIN-3 IN CARDIO-PROTECTION. Heart, 2014, 100, A9.2-A9.	2.9	0
323	An investigation into the effects of simulated ischaemic preconditioning on mitochondrial fusion in mouse embryonic fibroblasts. Journal of Cardiothoracic Surgery, 2015, 10, .	1.1	0
324	Incidence of left ventricular thrombi in reperfused STEMI patients detected by contrast-enhanced CMR. Journal of Cardiovascular Magnetic Resonance, 2015, 17, .	3.3	0

#	Article	IF	Citations
325	Quantification of the area-at-risk by T1 and T2 mapping CMR at 3T. Journal of Cardiovascular Magnetic Resonance, 2015, 17, P8.	3.3	0
326	Letter by Bulluck and Hausenloy Regarding Article, â€œDynamic Edematous Response of the Human Heart to Myocardial Infarction: Implications for Assessing Myocardial Area at Risk and Salvageâ€. Circulation, 2018, 137, 1748-1749.	1.6	0
327	David Garcia-Dorado: a true pioneer in cardiac ischaemia/reperfusion injury. Cardiovascular Research, 2019, 115, e177-e180.	3.8	0
328	The Fourth European-South African Cardiovascular Research Workshop. European Heart Journal, 2020, 41, 203-204.	2.2	0
329	Response to the letter to the editor regarding the study â€œImpact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortalityâ€•published in the American Heart Journal. American Heart Journal, 2020, 228, 117-118.	2.7	0
330	Combining Invasive Coronary Physiology With CMR for Long-Term Risk-Stratification in STEMI. JACC: Cardiovascular Imaging, 2021, 14, 1960-1962.	5.3	0
331	Novel Treatment Strategies. , 2012, , 261-291.		0
332	Preconditioning in the Heart. , 2013, , 51-101.		0
333	Nanoparticle delivery of cardioprotective therapies. Conditioning Medicine, 2020, 3, 18-30.	1.3	0